GlycoMimetics Inc GLYC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
Last | 04/24/24 EDT
1.85quote price arrow up+0.02 (+1.09%)
Volume
653,431
52 week range
1.11 - 3.53
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.85
  • 52 Week High3.53
  • 52 Week High Date01/23/24
  • 52 Week Low1.11
  • 52 Week Low Date10/25/23

Key Stats

  • Market Cap119.555M
  • Shares Out64.45M
  • 10 Day Average Volume0.86M
  • Dividend-
  • Dividend Yield-
  • Beta2.28
  • YTD % Change-21.4

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close1.85
  • 52 Week High3.53
  • 52 Week High Date01/23/24
  • 52 Week Low1.11
  • 52 Week Low Date10/25/23
  • Market Cap119.555M
  • Shares Out64.45M
  • 10 Day Average Volume0.86M
  • Dividend-
  • Dividend Yield-
  • Beta2.28
  • YTD % Change-21.4

RATIOS/PROFITABILITY

  • EPS (TTM)-0.58
  • P/E (TTM)-3.18
  • Fwd P/E (NTM)-3.12
  • EBITDA (TTM)-39.122M
  • ROE (TTM)-90.72%
  • Revenue (TTM)10,000.00
  • Gross Margin (TTM)-
  • Net Margin (TTM)-368,994.19%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/01/2024
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On GlycoMimetics Inc

 

Profile

MORE
GlycoMimetics, Inc. is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and for inflammatory diseases. It is developing a pipeline of glycomimetics, which are small molecules that mimic the structure of carbohydrates involved in biological processes, to inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection. Its...
Timothy Pearson
Independent Chairman of the Board
Harout Semerjian
President, Chief Executive Officer, Director
Brian Hahn
Chief Financial Officer, Senior Vice President - Finance
Address
9708 Medical Center Drive
Rockville, MD
20850
United States

Top Peers

SYMBOLLASTCHG%CHG
PROK
ProKidney Corp
2.71+0.18+7.11%
NVCT
Nuvectis Pharma Inc
6.71+0.12+1.82%
CTXR
Citius Pharmaceuticals Inc
0.7165-0.0508-6.6206%
VTGN
Vistagen Therapeutics Inc
4.72-0.11-2.28%
VOR
Vor Biopharma Inc
1.74-0.14-7.45%